Wittig Ilka, Groner Bernd
Georg Speyer Haus, Institute for Biomedical Research, Paul Ehrlich Strasse 42, D-60596 Frankfurt am Main, Germany.
Curr Drug Targets Immune Endocr Metabol Disord. 2005 Dec;5(4):449-63. doi: 10.2174/156800805774912999.
STAT5 belongs to a small family of transcription factors with dual functions. The seven signal transducers and activators of transcription (STAT) act as signaling components between the plasma membrane and the nucleus, and as transcription factors with specific DNA binding ability in the nucleus. STAT5 regulates the expression of genes, which determine important cellular phenotypes. It can promote proliferation and inhibit apoptosis, but is also involved in the regulation of differentiation between specific gene expression. STAT5 can also contribute to the transformed phenotype. In many leukemias and some solid tumors, STAT5 is constitutively activated through receptors or receptor associated tyrosine kinases and contributes to the survival and the proliferation of malignant cells. STAT5 activity appears to be limiting for these phenotypes. Inhibition of STAT5 in these tumor cells results in growth arrest and apoptosis. Targeting of STATs and other downstream mediators of oncogenic tyrosine kinases provides a promising strategy for tumor therapy, which might be refractory to resistance mechanisms incapacitating tyrosine kinase inhibitors. The well-studied steps in the activation of STAT5 and its roles in different subcellular compartments suggest original interference strategies, which could be used to inhibit its function. The challenge for drug developers will be the exploitation of defined protein-protein or protein-DNA interactions as targets of inhibition.
信号转导子和转录激活子5(STAT5)属于具有双重功能的一小类转录因子家族。七种信号转导子和转录激活子(STAT)既作为质膜与细胞核之间的信号传导成分,又作为在细胞核中具有特定DNA结合能力的转录因子。STAT5调节基因表达,这些基因决定重要的细胞表型。它可以促进增殖并抑制凋亡,还参与特定基因表达之间分化的调节。STAT5也可导致转化表型。在许多白血病和一些实体瘤中,STAT5通过受体或受体相关酪氨酸激酶被组成性激活,并促进恶性细胞的存活和增殖。STAT5活性似乎对这些表型具有限制作用。在这些肿瘤细胞中抑制STAT5会导致生长停滞和凋亡。靶向STATs及致癌酪氨酸激酶的其他下游介质为肿瘤治疗提供了一种有前景的策略,这对于使酪氨酸激酶抑制剂失效的耐药机制可能是难治的。对STAT5激活过程中经过充分研究的步骤及其在不同亚细胞区室中的作用提示了可用于抑制其功能的原始干扰策略。药物研发人员面临的挑战将是利用特定的蛋白质-蛋白质或蛋白质-DNA相互作用作为抑制靶点。